Anticancer effects of HESA-A in patients with metastatic colon cancer

Integrative Cancer Therapies

Volumn 8, Issue 1, 2009, Pages 71-74

  Ahmadi, Amrollah ^a,b,c   Mohagheghi, Mohammadali ^a   Karimi, Mehrdad ^b   Seyed Ali Golestanha, ^b   Naseri, Mohsen ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

^c NONE   (Iran)

Author keywords

Antioxidant; Cancer; Colorectal; HESA A; Side effects

Indexed keywords

ANTINEOPLASTIC AGENT; HERBACEOUS AGENT; HESA A; MORPHINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED STUDY; FEMALE; HEADACHE; HEMATOLOGICAL PARAMETERS; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER METASTASIS; MALE; NAUSEA; PRIORITY JOURNAL; VOMITING; WEAKNESS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CANCER CARE FACILITIES; COLONIC NEOPLASMS; FEMALE; HUMANS; IRAN; KARNOFSKY PERFORMANCE STATUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PLANT PREPARATIONS; PROSPECTIVE STUDIES;

EID: 61849131210     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735408327995     Document Type: Article

References (24)

1. Bullard KM, Rothenberger DA Colon, rectum and anus. In: Brunicardi FC, Andersen DK, Billiar TR, Hunter JG, eds. Schwartz's Principle of Surgery. 8 th ed. New York, NY: McGraw-Hill ; 2005: 1497-1505.
2. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007 ; 18: 581-592.
3. Ansari R., Mahdavinia M., Sadjadi A., et al. Incidence and age distribution of colorectal cancer in Iran: results of a population-based cancer registry. Cancer Lett. 2006 ; 240: 143-147.
4. Collier DA, Neidle S. Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthroquinones. J Med Chem. 1988 ; 31: 847-857.
5. Costello AJ A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: rationale, recruitment, and design issues. Urology. 2001 ; 57: 182-184.
6. Burk RF Selenium, an antioxidant nutrient. Nutr Clin Care. 2002 ; 5: 75-77.
7. Wang GQ, Dawsey SM, Li JY, et al. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of esophagus and stomach: results from the general population trial in Linxian, China. Cancer Epidemol Biomarkers Prev. 1994 ; 3: 161-166.
8. Melendez E. Titanium complex in cancer treatment. Crit Rev Oncol Hematol. 2002 ; 142: 309-315.
9. Fernandez-Banares F., Cabre E., Esteve M., et al. Serum selenium and risk of large colorectal adenomas in a geographical area with a low selenium status. Am J Gastroenterol. 2002 ; 97: 2103-2108.
10. Denkhaus SE, Salinkow K. Nickel essentiality, toxicity and carcinogenicity. Crit Rev Oncol Hematol. 2002 ; 42: 35-56.
11. Ji YJ, Xiao B., Wang ZH, Cui MZ, Lu YY The suppression effect of light-rate earth elements on proliferation of two cancer cell lines. Biomed Environ Sci. 2000 ; 13: 287-292.
12. Evangelov AM Vanadium in cancer treatment. Crit Rev Oncol Hematol. 2002 ; 42: 249-256.
13. Hiraoka K., Komiya S., Hamada T., Zenmyo M., Inove A. Osteosarcoma cell apoptosis induced by selenium. J Orthop Res. 2001 ; 19: 809-814.
14. Ahmadi A., inventor. Method of preparation of an antitumor herbal drug [HESA-A]. Islamic Republic of Iran patent 27741. 2002.
15. Ahmadi A., Naderi G., Asgary S. Evaluation of hepatoprotective potential of HESA-A (a marine compound) pretreatment against thioacetamide-induced hepatic damage in rabbits. Drugs Exp Clin Res. 2005 ; 31: 1-6.
16. Ahmadi A., Sadeghi Aliabadi H. Cytotoxicity and antitumor properties of a marine compound, HESA-A, on cancer cells. Daru. 2003 ; 11: 82-87.
17. Zeng H., Combs GF Jr. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem. 2008 ; 19: 1-7.
18. Caruso F., Rossi M. Antitumor titanium compounds. Mini Rev Med Chem. 2004 ; 4: 49-60.
19. Guo J., Deng W., Zhang L., Li C., Wu P., Mao P. Prediction of prostate cancer using hair trace element concentration and support vector machine method. Biol Trace Elem Res. 2007 ; 116: 257-272.
20. Hajhashemi V., Ghafghazi T., Balali M., et al. Toxicological studies on an anticancer drug (HESA-A) with marine origin. Med J Islam Acad Sci. 2001 ; 14: 145-149.
21. Ahmadi A., Mohgheghi MA, Sharif-Tabrizi A. Introducing the therapeutic effects of HESA-A on osteosarcoma included in rabbits. Paper presented at: Proceedings of the First National Congress on Cancer Research ; April 5-8, 2001 ; Orumiah, Iran.
22. Sadeghi-Aliabadi H., Ahmadi A. Cytotoxicity and antitumor properties of a marine compound on cancer cell (HESA-A). Med J Islam Acad Sci. 2000 ; 13: 55-61.
23. Fazly Bazzaz BS HESA-A, its cytotoxicity and mutagenicity. J Oncol Pharm Pract. 2006 ; 12: 60.
24. Ahmadi A. Analysis of HESA: Report of Atomic Energy Organization of Iran (AEOI). Tehran, Islamic Republic of Iran: Research Division, AEOI ; 2004.